Showing 1 to 10 of 19
| Title | Consultation | Type | Consultation end date | Sort date |
|---|---|---|---|---|
| Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211] | Draft guidance | Technology appraisal guidance | Type:17 July 2025 | 20250717 |
| Pegzilarginase for treating arginase-1 deficiency [ID4029] | Draft guidance | Highly specialised technology | Type:17 July 2025 | 20250717 |
| Suspected sepsis: recognition, diagnosis and early management | Draft guidance consultation | NICE guideline | Type:18 July 2025 | 20250718 |
| Low energy contact X-ray brachytherapy for rectal cancer | Interventional procedure consultation | Interventional procedures guidance | Type:23 July 2025 | 20250723 |
| Leadless cardiac pacemaker implantation for bradyarrhythmias | Interventional procedure consultation | Interventional procedures guidance | Type:23 July 2025 | 20250723 |
| Teprotumumab for treating thyroid eye disease [ID6432] | Draft guidance: 1 | Technology appraisal guidance | Type:23 July 2025 | 20250723 |
| Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394] | Draft guidance: 1 | Technology appraisal guidance | Type:23 July 2025 | 20250723 |
| Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256] | Draft guidance | Technology appraisal guidance | Type:25 July 2025 | 20250725 |
| Delgocitinib for treating moderate to severe chronic hand eczema [ID6408] | Draft guidance | Technology appraisal guidance | Type:28 July 2025 | 20250728 |
| Osteoporosis | Topic engagement | Quality standard | Type:29 July 2025 | 20250729 |